
# 2018 Pricing Reform: Will Takeda Exit the Japanese Pharma Market?

Japan Pharma & Governance Tour: UBS Securities e-Projection K.K.

July 12, 2018


### Three Forces Determining the Direction of Healthcare

Shape of the market will depend on the priorities and the balance of the forces



### Broken NHI System Casting a Shadow on Healthcare


Structural and operational malfunction leading to de-prioritization of innovation



### '18 Reform: Changing the Environment Dramatically

#### Incentives were repealed without any compensative measures Initiatives

Revision of the Price Maintenance Premium



**Implications** 

Deceleration in market growth of new drugs



Flexible re-pricing in response to "Market Expansion" allowing massive price cuts to happen anytime



Decreasing the consistency of the business




Measures to estimate the intrinsic value of the products, e.g. HTA, failed to be implemented effectively



Possibility of erroneous initial prices granted

## Ramifications of the '18 Pricing Reform

Business prospects will deteriorate with low predictability early in the lifecycle





Takeda: Time to say da svidania to Japan?







■Consultant and pharmaceutical forecasting expert with global and local experience spanning across areas of commercial and R&D. Prior to being the president of e-Projection, he was a Director of Sales Forecasting and Analytics at Takeda Pharmaceuticals. Before Takeda, he worked at Abbvie, engaged in various positions in Global Marketing and the Japan affiliate. Relevant education includes Ph.D. in medicine from Shinshu University and MBA from University of Chicago Booth School of Business with honors.

Website: <a href="http://e-projection.com/">http://e-projection.com/</a>

E-mail: tosh.nagate@e-projection.com